3 Stocks Pushing The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 12 points (-0.1%) at 16,797 as of Wednesday, June 18, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,344 issues advancing vs. 1,611 declining with 185 unchanged.

The Drugs industry currently sits up 0.1% versus the S&P 500, which is unchanged. Top gainers within the industry include Shire ( SHPG), up 2.5%, Teva Pharmaceutical Industries ( TEVA), up 1.2%, Biogen Idec ( BIIB), up 1.2%, Allergan ( AGN), up 1.1% and Actavis ( ACT), up 0.9%. On the negative front, top decliners within the industry include Gilead ( GILD), down 1.0%, and Novo Nordisk A/S ( NVO), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Abbott Laboratories ( ABT) is one of the companies pushing the Drugs industry higher today. As of noon trading, Abbott Laboratories is up $0.24 (0.6%) to $40.10 on average volume. Thus far, 2.4 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 6.3 million shares. The stock has ranged in price between $39.74-$40.21 after having opened the day at $39.84 as compared to the previous trading day's close of $39.86.

Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $59.9 billion and is part of the health care sector. Shares are up 4.0% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts who rate Abbott Laboratories a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and deteriorating net income. Get the full Abbott Laboratories Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Regeneron Pharmaceuticals ( REGN) is up $1.62 (0.5%) to $304.24 on light volume. Thus far, 254,221 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 874,600 shares. The stock has ranged in price between $301.31-$304.64 after having opened the day at $301.99 as compared to the previous trading day's close of $302.62.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $30.5 billion and is part of the health care sector. Shares are up 9.9% year-to-date as of the close of trading on Tuesday. Currently there are 6 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and weak operating cash flow. Get the full Regeneron Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, AstraZeneca ( AZN) is up $0.65 (0.9%) to $74.59 on light volume. Thus far, 1.5 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 5.6 million shares. The stock has ranged in price between $74.33-$74.85 after having opened the day at $74.63 as compared to the previous trading day's close of $73.94.

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. AstraZeneca has a market cap of $93.0 billion and is part of the health care sector. Shares are up 24.5% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst who rates AstraZeneca a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Roku, Amazon, Teladoc, Weyerhaeuser: 'Mad Money' Lightning Round

Roku, Amazon, Teladoc, Weyerhaeuser: 'Mad Money' Lightning Round

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Cramer: 10 Points to Consider

Cramer: 10 Points to Consider

The 5 Best Dividend Aristocrats For 2018

The 5 Best Dividend Aristocrats For 2018

Lam Research: Cramer's Top Takeaways

Lam Research: Cramer's Top Takeaways